Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE8B | O95263 | 3/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | PDE1A | P54750 | 2/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199421 | 0.99 | ADORA2A (0.41) | PDE8BTLR7ADORA2APIK3CATLR8 | |
| SCHEMBL2201074 | 0.80 | TLR7 (0.57) | PDE8BTLR7ADORA2APIK3CATLR8 | |
| SCHEMBL3441183 | 0.74 | TLR7 (0.47) | PDE8BTLR7ADORA2APDE1APDE1B | |
| SCHEMBL3320276 | 0.69 | ADORA2A (0.40) | PDE8BTLR7ADORA2APDE1APDE1B | |
| SCHEMBL3321834 | 0.68 | PDE5A (0.40) | PDE8BADORA2APDE1APDE1BPDE1C | |
| SCHEMBL14123272 | 0.68 | PDE8B (0.42) | PDE8BTLR7TLR8ADORA3 | |
| SCHEMBL2198368 | 0.68 | PDE8B (0.42) | PDE8BTLR7ADORA2APIK3CATLR8 | |
| SCHEMBL5401433 | 0.68 | TLR7 (0.40) | TLR7ADORA2ATLR8ADORA3ADORA2B | |
| SCHEMBL2197755 | 0.67 | TLR7 (0.44) | PDE8BTLR7ADORA2APIK3CAPDE1A | |
| SCHEMBL2198664 | 0.65 | PDE8B (0.40) | PDE8BTLR7ADORA2APIK3CATLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | PDE8B 1844/4885TLR7 38/4885ADORA2A 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.